参考文献/References:
[1].Goldstein JL,Brown MS. A century of cholesterol and coronaries:from plaques to genes to statins[J]. Cell,2015,161(1):161-172.
[2].诸骏仁,高润霖,赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志,2016,31(10):937-953.
[3].Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:a report of theAmerican college of cardiology/American heart association task force on clinical practice guidelines[J]. Circulation,2019,139(25):e1082-e1143.
[4].Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
[5].Masana L,Girona J,Ibarretxe D,et al. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis[J]. J Clin Lipidol,2018,12(2):292-299.e3.
[6].Karagiannis AD,Mehta A,Dhindsa DS,et al. How low is safe?The frontier of very low(<30 mg/dL)LDL cholesterol[J]. Eur Heart J,2021,42(22):2154-2169.
[7].中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志,2016,44(10):833-853.
[8].中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志,2023,51(3):221-255.
[9].Mahmood SS,Levy D,Vasan RS,et al. The Framingham Heart Study and the epidemiology of cardiovascular disease:a historical perspective[J]. Lancet,2014,383(9921):999-1008.
[10].Stamler J,Neaton JD,Cohen JD,et al. Multiple risk factor intervention trial revisited:a new perspective based on nonfatal and fatal composite endpoints,coronary and cardiovascular,during the trial[J]. J Am Heart Assoc,2012,1(5):e003640.
[11].Pokharel Y,Tang Y,Bhardwaj B,et al. Association of low-density lipoprotein pattern with mortality after myocardial infarction:insights from the TRIUMPH study[J]. J Clin Lipidol,2017,11(6):1458-1470.e4.
[12]. Pietil? K,Tenkanen L,M?ntt?ri M,et al. How to define coronary heart disease in register-based follow-up studies:experience from the Helsinki Heart Study[J]. Ann Med,1997,29(3):253-259.
[13]. Sun L,Clarke R,Bennett D,et al. Causal associations of blood lipids with risk of ischemic stroke and intracerebral hemorrhage in Chinese adults[J]. Nat Med,2019,25(4):569-574.
[14]. Ma C,Gurol ME,Huang Z,et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage:a prospective study[J]. Neurology,2019,93(5):e445-e457.
[15]. Phuah CL,Raffeld MR,Ayres AM,et al. Subacute decline in serum lipids precedes the occurrence of primary intracerebral hemorrhage[J]. Neurology,2016,86(22):2034-2041.
[16]. Rist PM,Buring JE,Ridker PM,et al. Lipid levels and the risk of hemorrhagic stroke among women[J]. Neurology,2019,92(19):e2286-e2294.
[17]. Wen CP,Lee YC,Sun YT,et al. Low-density lipoprotein cholesterol and mortality in patients with intracerebral hemorrhage in Taiwan[J]. Front Neurol,2022,12:793471.
[18].Amarenco P,Bogousslavsky J,Callahan A 3rd,et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med,2006,355(6):549-559.
[19]. Jin X,Chen H,Shi H,et al. Lipid levels and the risk of hemorrhagic stroke:a dose-response meta-analysis[J]. Nutr Metab Cardiovasc Dis,2021,31(1):23-35.
[20]. Rosenson RS,Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology[J]. Atherosclerosis,1998,140(2):271-280.
[21].Lauer A,Greenberg SM,Gurol ME. Statins in intracerebral hemorrhage[J]. Curr Atheroscler Rep,2015,17(8):46.
[22].Gu X,Li Y,Chen S,et al. Association of lipids with ischemic and hemorrhagic stroke:a prospective cohort study among 267 500 Chinese[J]. Stroke,2019,50(12):3376-3384.
[23]. Giugliano RP,Wiviott SD,Blazing MA,et al. Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol:a prespecified analysis of the IMPROVE-IT trial[J]. JAMA Cardiol,2017,2(5):547-555.
[24]. Schwartz GG,Gabriel Steg P,Bhatt D L,et al. Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol:a propensity score-matched analysis of the ODYSSEY OUTCOMES trial[J]. Circulation,2021,143(11):1109-1122.
[25]. Robinson JG,Farnier M,Krempf M,et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1489-1499.
[26].Sabatine MS,Giugliano RP,Wiviott SD,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1500-1509.
[27]. Huang X,Abbott RD,Petrovitch H,et al. Low LDL cholesterol and increased risk of Parkinson’s disease:prospective results from Honolulu-Asia aging study[J]. Mov Disord,2008,23(7):1013-1018.
[28]. Robinson JG. Low LDL-C levels:likely no short-term cognitive harm[J]. J Am Coll Cardiol,2020,75(18):2294-2296.
[29]. Harvey PD,Sabbagh MN,Harrison JE,et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials:a meta-analysis of individual patient data[J]. Eur Heart J,2018,39(5):374-381.
[30].Orth M,Bellosta S. Cholesterol:its regulation and role in central nervous system disorders[J]. Cholesterol,2012,2012:292598.
[31]. Everett BM,Mora S,Glynn RJ,et al. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels(<30 mg/dl)with rosuvastatin 20 mg daily(from JUPITER)[J]. Am J Cardiol,2014,114(11):1682-1689.
[32]. Schmidt AF,Swerdlow DI,Holmes MV,et al. PCSK9 genetic variants and risk of type 2 diabetes:a mendelian randomisation study[J]. Lancet Diabetes Endocrinol,2017,5(2):97-105.
[33].Ference BA,Robinson JG,Brook RD,et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes[J]. N Engl J Med,2016,375(22):2144-2153.
[34]. Lotta LA,Sharp SJ,Burgess S,et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes:a meta-analysis[J]. JAMA,2016,316(13):1383-1391.
[35]. Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[36]. Guan XM,Wu SL,Yang XL,et al. Association of total cholesterol,low-density lipoprotein cholesterol,and non-high-density lipoprotein cholesterol with atherosclerotic cardiovascular disease and cancer in a Chinese male population[J]. Int J Cancer,2018,142(6):1209-1217.
[37]. Lyu Z,Li N,Wang G,et al. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males:a prospective cohort study[J]. Int J Cancer,2019,144(12):2972-2984.
[38]. Benn M,Tybj?rg-Hansen A,Stender S,et al. Low-density lipoprotein cholesterol and the risk of cancer:a mendelian randomization study[J]. J Natl Cancer Inst,2011,103(6):508-519.
[39].Alsheikh-Ali AA,Trikalinos TA,Kent DM,et al. Statins,low-density lipoprotein cholesterol,and risk of cancer[J]. J Am Coll Cardiol,2008,52(14):1141-1147.
[40].Johnson KE,Siewert KM,Klarin D,et al. The relationship between circulating lipids and breast cancer risk:a mendelian randomization study[J]. PLoS Med,2020,17(9):e1003302.
[41]. Kho PF,Amant F,Annibali D,et al. Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer[J]. Int J Cancer,2021,148(2):307-319.
[42]. Rossin D,Calfapietra S,Sottero B,et al. HNE and cholesterol oxidation products in colorectal inflammation and carcinogenesis[J]. Free Radic Biol Med,2017,111:186-195.
[43]. Bakiri L,Hamacher R,Gra?a O,et al. Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation[J]. J Exp Med,2017,214(5):1387-1409.
[44].Cortés Sempere M,Rodríguez Fanjul V,Sánchez Pérez I,et al. The role of the NFkappaB signalling pathway in cancer[J]. Clin Transl Oncol,2008,10(3):143-147.
[45]. Robinson JG,Rosenson RS,Farnier M,et al. Safety of very low low-density lipoprotein cholesterol levels with?alirocumab:pooled data from randomized trials[J]. J Am Coll Cardiol,2017,69(5):471-482.
[46]. Yusuf S,Bosch J,Dagenais G,et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease[J]. N Engl J Med,2016,374(21):2021-2031.
[47]. Persons JE,Robinson JG,Coryell WH,et al. Longitudinal study of low serum LDL cholesterol and depressive symptom onset in postmenopause[J]. J Clin Psychiatry,2016,77(2):212-220.
[48]. Ayesa-Arriola R,Canal Rivero M,Delgado-Alvarado M,et al. Low-density lipoprotein cholesterol and suicidal behaviour in a large sample of first-episode psychosis patients[J]. World?J Biol Psychiatry,2018,19(sup3):S158-S161.
[49]. Johannesen CDL,Langsted A,Mortensen MB,et al. Association between low density lipoprotein and all cause and cause specific mortality in Denmark:prospective cohort study[J]. BMJ,2020,371:m4266.
[50]. Rong S,Li B,Chen L,et al. Association of low-density lipoprotein cholesterol levels with more than 20-year risk of cardiovascular and all-cause mortality in the general population[J]. J Am Heart Assoc,2022,11(15):e023690.
[51]. Yi SW,An SJ,Park HB,et al. Association between low-density lipoprotein cholesterol and cardiovascular mortality in statin non-users:a prospective cohort study in 14.9 million Korean adults[J]. Int J Epidemiol,2022,51(4):1178-1189.
[52]. Ravnskov U,McCully KS. Review and hypothesis:vulnerable plaque formation from obstruction of vasa vasorum by homocysteinylated and oxidized lipoprotein aggregates complexed with microbial remnants and LDL autoantibodies[J]. Ann Clin Lab Sci,2009,39(1):3-16.
[53]. Ravnskov U. High cholesterol may protect against infections and atherosclerosis[J]. QJM,2003,96(12):927-934.
[54]. David LA,Maurice CF,Carmody RN,et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature,2014,505(7484):559-563.
[55]. Devkota S,Wang Y,Musch MW,et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice[J]. Nature,2012,487(7405):104-108.
[56]. Mueller M,Thorell A,Claudel T,et al. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity[J]. J hepatol,2015,62(6):1398-1404.
[57]. Wang Z,Klipfell E,Bennett BJ,et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J]. Nature,2011,472(7341):57-63.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(11):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(11):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[3]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(11):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[4]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(11):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[5]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(11):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[6]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(11):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[7]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(11):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[8]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(11):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[9]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(11):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[10]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(11):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[11]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(11):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]